TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in Freezing of Gait Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ∆SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS‐III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Eyelid gland quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lacrimal river height measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear secretion measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of microbial load of E. coli and E. faecalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pain associated with first bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thin ideal internalization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: use of communication skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: therapeutic glycaemic response (HbA1c <53 mmol/mol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: need for treatment intensification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: adjusted mean reductions in liver fat and adipose tissue volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardioembolic stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: Atrial fibrillation risk
Endpoint domain: Mortality/survival
Primary endpoint: Peripheral artery disease risk
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Theory of Mind (ToM) tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in negative and cognitive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds of moderate-severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sweet food choice and intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of death, myocardial infarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postoperative Acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage reduction in 28-day adjusted focal seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of a new antiretroviral drug
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of TRAEs
Endpoint domain: Adverse events/effects
Primary endpoint: MPG (mean plasma glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MAGE (mean amplitude of glycemic excursions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC24 (area under the curve over 24 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade 3/4 lymphopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Regression of CIN lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in p16/Ki‐67 cytological test status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of hr‐HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T cell immune function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preference for glasses prescribed using SR vs AR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average chest compression depth (CCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate chest compression depth (CCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average force of compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of virally suppressed adolescents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 20-year cumulative failure incidence for revision surgery
Endpoint domain: Mortality/survival
Primary endpoint: mean femoral head penetration at 20 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SCALE score improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBS score improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of intestinal parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pain levels during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARI (Adhesive Remnant Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placement success rate at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma luteinizing hormone (LH) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean change in monthly child cotinine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Cooperative Study–Activities of Daily Living (ADCS-ADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Dementia Rating Sum of Boxes (CDR-sb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive oxygen species emission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coronary revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TOPICOP score improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: DLQI score of 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EQ-5D-3L Pain/Discomfort dimension score of 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activity Impairment improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: endoscopic sinus performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in treatment outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: symptomatic improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional gains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in VISA-A score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delivery at normal working hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presentation for spontaneous labour or rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in urinary cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kt/v
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance for examination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attendance at emergency appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Preventative intervention received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Child reported pain score for needle prick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFV-DP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to undergo colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBL and TBL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory factors and fibrinolysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score on postoperative days 1 and 3
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Choice of delivery mode
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: plasma monocyte chemotactic protein‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma interleukin‐1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma interleukin‐17a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clarity of radiocarpal joint visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obscuration of joint lines by orthopedic hardware
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for 20° view by radiologists and technologists
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Drug discontinuation due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PRTEE score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amount and volume of ventilations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking abstinence rate at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking abstinence rate at 3-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to run 2 miles pain free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of time in range (TIR, 3.9-10 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycemic variability (standard deviation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose management indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: annual change in tibial cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in health due to yoga practice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for inpatient treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social inclusion
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of treated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total length of treated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intradialytic hypotension event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantification of SUVN-G3031 in human plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiemetic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: earlier discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: less frequent use of opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Equity in access to research
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-centered research outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Women's awareness of available assets
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motivation for help-seeking behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total events of the primary outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exceptional benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D-5L Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ventilatory peak pressure over PEEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: EAdi peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of prescription checks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median total number of treatments till symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete symptom resolution after initial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymptomatic at treatment completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean root coverage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete coverage of all recessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HLA-DR expression in conjunctival cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6 concentration percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-8 concentration percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mother-to-infant bonding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pregnancy-specific anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: moderate/severe exacerbation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: severe exacerbation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: discordance in VTE chemoprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median marginal bone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Horizontal bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Profilometric change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of unintentional movement during dermal puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pre- and post-assessment scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean 24‐hour systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in nausea and emesis total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in oral nutrition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global satisfaction of treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete inhibition of C. albicans CFU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean apparent terminal half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax following multiple ascending doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event (AE) profile
Endpoint domain: Adverse events/effects
Primary endpoint: Pupil dilation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent melanoma diagnoses
Endpoint domain: Mortality/survival
Primary endpoint: 3-year re-treatment rates for recurrent bladder outlet obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge readiness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants with accurate label comprehension
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with current medical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Obtaining employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Days worked in therapeutic workplace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PDN symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily glycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: performance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean percentage change from baseline in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in focal seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Intention to vaccinate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expansion in the molar region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distinguishing sika deer from hybrid offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective measures of AD severity (memory and mood)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Survival without requiring IMV
Endpoint domain: Mortality/survival
Primary endpoint: COVID-19-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: decrease in rest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of T-APS
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Assessment of Cancer Therapy-Breast subscale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Assessment of Cancer Treatment Neurotoxicity subscale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: visual activation to aversive pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-rated ability to deliver MAT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: KOOS overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activities of daily living subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sports and recreation subscore
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in 24-hour SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean systolic AOBP reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tibial cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word recognition score loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPAP adherence at one month
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: total sleep time during titration night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep efficiency during titration night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional immune responses measured by OPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stage of behavioral change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PGA‐OA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time for bladder catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time for ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time for minor hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes